SCM
RGNX icon

Silvant Capital Management’s Regenxbio RGNX Stock Holding History

Silvant Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,732
Closed -$124K – 337
2022
Q1 		$124K Hold
3,732
– – 0.02% 210
2021
Q4 		$122K Sell
3,732
-239
-6% -$8.14K 0.02% 208
2021
Q3 		$166K Hold
3,971
– – 0.03% 195
2021
Q2 		$154K Hold
3,971
– – 0.02% 205
2021
Q1 		$135K Hold
3,971
– – 0.02% 211
2020
Q4 		$180K Hold
3,971
– – 0.03% 191
2020
Q3 		$109K Hold
3,971
– – 0.02% 212
2020
Q2 		$146K Hold
3,971
– – 0.03% 195
2020
Q1 		$129K Hold
3,971
– – 0.03% 183
2019
Q4 		$163K Hold
3,971
– – 0.03% 195
2019
Q3 		$141K Buy
3,971
+1,400
+54% +$56.7K 0.03% 193
2019
Q2 		$132K Hold
2,571
– – 0.02% 214
2019
Q1 		$147K Buy
+2,571
New +$127K 0.03% 206

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Silvant Capital Management's RGNX Position: Q2 2022 in Review

Silvant Capital Management sold out of Regenxbio (RGNX) in Q2 2022, closing a stake of 3,732 shares — an estimated $124K sold.

Silvant Capital Management first reported a position in RGNX in Q1 2019 and held it in 13 quarters. The position peaked at $180K in Q4 2020. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2022.

  • Silvant Capital Management reported no remaining Regenxbio position as of Q2 2022 after selling out during the quarter.
  • Silvant Capital Management sold 3,732 Regenxbio shares in Q2 2022, an estimated $124K.
  • Silvant Capital Management first reported a position in Regenxbio in Q1 2019 and held it in 13 quarters.
  • Silvant Capital Management's Regenxbio position peaked at $180K in Q4 2020.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2022.

Based on Silvant Capital Management's 13F filing for Q2 2022, filed 3 Aug 2022.